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Rationale & Objective: Outcomes reported in trials involving patients with 
autosomal dominant polycystic kidney disease (ADPKD) are heterogeneous and 
rarely include patient-reported outcomes. We aimed to identify critically important 
consensus-based core outcome domains to be reported in trials in ADPKD.  
Study Design: An international two-round online Delphi survey was conducted in 
English, French, Korean languages.  
Setting & Participants: Patients/caregivers and health professionals completed a 9-
point Likert scale (7-9 indicating critical importance) and a Best-Worst Scale.  
Analytical Approach: The absolute and relative importance of outcomes were 
assessed. Comments were analyzed thematically.  
Results: 1014 participants (603 [60%] patients/caregivers, 411 [40%] health 
professionals) from 56 countries completed Round 1, and 713 (70%) completed 
Round 2. The prioritized outcomes were kidney function (importance score 8.6), end-
stage kidney disease (ESKD, 8.6), death (7.9), blood pressure (7.9), kidney cyst 
size/growth (7.8) and cerebral aneurysm (7.7). Kidney cyst-related pain was the 
highest rated patient-reported outcome by both stakeholder groups. Seven themes 
explained the prioritization of outcomes: protecting life and health, directly 
encountering life-threatening and debilitating consequences, specificity to ADPKD, 
optimizing and extending quality of life, hidden suffering, destroying self-confidence, 
and lost opportunities.  
Limitations: Study design precluded involvement from those without access to 
internet or limited computer literacy. 
Conclusions: Kidney function, ESKD, and death were the most important outcomes 
to patients, caregivers and health professionals. Kidney cyst-related pain was the 
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highest rated patient-reported outcome. Consistent reporting of these top prioritized 




Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
genetic cause of chronic kidney disease. Up to 70% of patients with ADPKD progress 
to end-stage kidney disease (ESKD) by the age of 65 years1,2. Whilst kidney function 
often remains stable for many years after diagnosis, patients with ADPKD often 
suffer from debilitating symptoms, such as pain, which are related to kidney cyst 
growth and enlargement3-6, and they are at risk of extra-renal complications, including 
stroke from ruptured intracranial aneurysm and severe polycystic liver disease7.  
 
Whilst there is some evidence to support lifestyle interventions (e.g. salt restriction8) 
and therapeutic agents (e.g. tolvaptan) in improving kidney function and total kidney 
volume (TKV)9-13; outcomes important to patients with ADPKD and their caregivers 
such as kidney pain and fatigue14, anxiety/psychosocial distress15, are infrequently 
reported in trials in ADPKD7,16-18.  Trials in ADPKD most frequently report surrogate 
outcomes including kidney function, kidney/cyst volume, and blood pressure19. As 
part of the Standardized Outcomes in Nephrology – Polycystic Kidney Disease 
(SONG-PKD) initiative20, the aim of this study was to generate consensus among 
patients, caregivers and health professionals on critically important outcomes to be 
reported in trials in ADPKD. This will inform the development of a core outcome set, 
defined as an “agreed minimum set of outcomes to be reported in all trials”21,22, which 
can lead to improved consistency in reporting outcomes important to patients and 







The Delphi technique23 is an internationally accepted approach used to establish 
consensus on core outcome sets for trials in nephrology and other disciplines24-28. The 
participants’ anonymities are maintained, and they are able to complete the survey 
independently and allow for widespread international participation through online 
dissemination29. The survey was conducted online in three languages (English, 
French, Korean).  The English survey was translated into French and Korean by a 
bilingual health professional and cross-checked by a second bilingual professional to 
ensure accuracy.  The survey was pilot tested by members of the SONG-PKD 
Steering Group including three patients with ADPKD.  There were two iterative 
rounds completed by a panel of participants with experience or expertise in ADPKD.  
Due to stability in results from Round 1 and 2, we did not proceed with an additional 
round.  In the second round, participants could review their own score from Round 1, 
the distribution of scores (overall, patients/caregivers, health professionals) and 
comments provided by participants. The SONG-PKD Delphi process is shown in 
Figure S1.  
 
Participant selection and recruitment  
Patients, caregivers and health professionals with an experience in ADPKD were 
eligible to participate. Patients/caregivers (aged 18 years or older) included patients 
with ADPKD across all stages of chronic kidney disease (CKD stages 1-5; dialysis 
[hemodialysis, peritoneal dialysis], transplantation) and family members and friends. 
Health professionals included physicians (nephrologists, hepatologists, surgeons, 
geneticists), nurses, allied health professionals, researchers, policy makers, industry 




To include a diverse range of participants, we used multiple recruitment strategies. 
Patients were recruited from hospitals, patient/consumer organizations, the SONG 
database and social media. Health professionals were recruited through the SONG 
database, investigator networks and professional organizations (Table S1). 
Participants received an email invitation including a link to the survey after 
registering their email on the SONG website (www.songinitiative.org). Ethics 
approval was provided by the University of Sydney (2015-228) and participating 
institutions (Table S1).  
 
Data collection  
Selection of outcome domains: The 41 outcome domains included in the survey were 
identified from a systematic review of ADPKD trials and a study of patient/caregiver 
priorities for outcomes in ADPKD14. The order in which outcome domains appeared 
in the survey was random and each outcome was accompanied by a plain language 
definition (Table S2). The SONG-PKD Steering Group and investigators reviewed the 
list of outcomes. The survey was administered online using Qualtrics (Qualtrics 
software, Provo, UT, United States) from June 2018 to February 2019.  
 
Round 1: Participants scored the importance of each of the 41 outcome domains using 
a 9-point Likert scale. Scores 1-3 indicated “limited importance”, 4-6 indicated 
“important but not critical” and 7-9 indicated “critical importance” (Figure S1), based 
on the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) process30. For each outcome, there was an option to enter comments in 
free-text boxes. Participants also had an “unsure” option and could suggest new 
outcomes. New outcomes suggested by more than 10% of participants were 
considered for inclusion in the second round. Outcomes with a mean score of less 
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than 6 or a median score of less than 7 in both groups (patients/caregivers and health 
professionals) were excluded in Round 2. The comments from each outcome in 
Round 1 were separately evaluated to determine any overlap between outcome 
domains and the need to revise the outcome domains for Round 2.  
 
Round 2: 17 outcomes were included in Round 2. Participants could review their own 
scores from Round 1 as well as the distribution of scores (overall and divided 
according to status of patients/caregivers and health professionals) displayed as 
percentage of participants in a column graph. De-identified comments from Round 1 
were provided. After reviewing these results, participants were asked to re-rate the 
outcomes using the 9-point Likert scale following the same methods used for Round 
1. On completion of rating all outcomes, participants were asked to complete a Best-
Worst Scale (BWS) survey, to examine the relative importance of each outcome24. 
The BWS consists of choice tasks in which a participant is asked to indicate the best 
and the worst items/options, with the overall aim to obtain a ranking of items in the 
order of preference31,32.  Five Best-Worst choice sets, each containing six of 17 
outcomes selected using a balanced, incomplete block design were presented to each 
participant. For each Best-Worst choice set, participants had to select the most 
important and the least important outcome.  
 
Data analysis  
Quantitative analysis: For every outcome in each round, the mean score, median 
score and proportion of participants who rated the outcomes as critically important 
(from 7 to 9) were calculated. The scores were separately calculated for 
patients/caregivers and health professionals, and their mean differences in scores as 
well as changes between two survey rounds were analyzed using a t-test. Results from 
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the BWS survey were incorporated in a multinomial logistic regression model to 
determine the relative importance. Utility functions containing all outcomes and 
interaction terms for participant characteristics were constructed. Subsequently, the 
mean regression coefficients of these functions provided the relative importance 
scores for each outcome32, where a scale of 1 represented the “least important” and 9 
the “most important”. Statistical analyses were performed using Stata (version 14.0, 
StataCorp LP, College Station, TX, United States), SPSS (IBM SPS Statistics for 
Windows, Version 25.0. Armonk, NY), Excel (Microsoft Corporation, Product version 
16.0), and NLOGIT V6 (Econometric Software Inc.) for the BWS.  
 
Definition of consensus for core outcomes: Due to unknown distribution of scores, the 
threshold for consensus for the core outcomes domains could not be pre-specified. 
The Delphi survey aimed to identify 3-5 outcome domains that were critically 
important to both stakeholder groups. “Consensus” for the critical outcome domains 
was defined based on both patient/caregiver and health professional groups yielding 
median scores of ≥7 and mean scores ≥7, as well as the proportions of both 
stakeholder groups rating the outcome as “critically important (defined as scores 7-9)” 
being greater than 75% in Round 2. These thresholds were discussed and approved by 
the SONG-PKD Steering Group. The scores obtained from the BWS were used to 
examine the relative differences in preference scores between patients/caregivers and 
health professionals.   
 
Qualitative analysis: The comments from the survey were imported into 
HyperRESEARCH (Version 3.7, Randolph, MA, United States) software for data 
analysis. Using thematic analysis, investigators coded the text (in English, Korean 
[YC], French [BS]) and inductively identified themes focusing on reasons for ratings, 
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differences between stakeholder groups and changes in scores across rounds. A third 
investigator (AT) read the qualitative data and reviewed the preliminary analysis to 




Participant characteristics  
In Round 1, 1014 participants from 56 countries completed the survey, of whom 603 
(60%) were patients/caregivers and 411 (40%) were health professionals. In Round 2, 
713 participants (70% overall retention rate) from 47 countries completed the survey, 
which included 406 (57%) patients/caregivers and 307 (63%) health professionals 
(Tables 1, 2).  
 
Of the 406 patients/caregivers who completed both rounds, 275 (74%) were patients 
not receiving kidney replacement therapy, 7 (2%) were on peritoneal dialysis, 22 (6%) 
were on hemodialysis, and 68 (18%) were kidney transplant recipients. Overall 65 
caregivers/family members (total N>406 due to multiple roles, e.g. patients who were 
also caregivers to other family members affected by ADPKD) from 23 countries 
participated, including from the Republic of Korea (23%), United Kingdom (22%), 
United States (21%), Australia (14%) and Canada (7%). Of the 307 health 
professionals who also completed both rounds, 214 (70%) were nephrologists, 36 
(12%) were researchers and 32 were nurses (10%). Dietitians, policy makers, 
surgeons, a geneticist, a hepatologist, industry representatives, and a psychologist also 
participated. Health professionals were from 41 countries, including Australia (18%), 
France (13%), United States (12%), United Kingdom (8%), Republic of Korea (8%) 




Rating scores  
Round 1: The mean and median scores and the proportions of participants scoring the 
outcomes from 7-9 separated by patients/caregivers and health professionals for each 
of the 41 outcome domains in Round 1 are provided in Table S3. The top five 
outcomes with the highest mean scores for patients/caregivers were kidney function 
(8.5), ESKD (8.4), cerebral aneurysm (8.0), kidney cyst size/growth (8.0) and blood 
pressure (7.9). For health professionals, the top five outcomes were kidney function 
(8.4), ESKD (8.4), death (7.8), cerebral aneurysm (7.5) and blood pressure (7.5). 
Twenty-four outcomes had mean scores less than 6.0 or median scores less than 7.0 
across both groups and were excluded from Round 2. Although fatigue did not meet 
the criteria based on mean and median scores, it was included in Round 2 to ensure 
the inclusion of at least five patient-reported outcomes in Round 2. Kidney cyst 
infection and cyst related pain/bleeding were combined as kidney cyst 
pain/bleeding/infection due to overlap based on comments (i.e. prioritized due to pain 
caused by bleeding or infection) and similarity in scores. None of the new outcomes 
were suggested by more than 10% of the participants (Table S4) and were therefore 
not included in the next round.  
 
Round 2: For each of the 17 outcome domains in Round 2, the mean and median 
scores and proportion of participants scoring the outcome as “critically important” are 
shown in Table S5. The top five prioritized outcomes from all participants were 
kidney function (8.6), ESKD (8.6), death (7.9), blood pressure (7.9) and kidney cyst 
size/growth (7.8). However, the top five outcomes list for patients/caregivers included 
cerebral aneurysm (7.8) instead of death. In general, top five outcomes according to 
language subtypes were comparable, except inclusion of cerebral aneurysm instead of 
kidney cyst size/growth and death in French and Korean, respectively (Table S6). The 
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mean scores of outcomes were generally higher for female patients/caregivers 
compared to male participants for all outcomes (Table S7).    
 
Changes in scores from Round 1 to 2 
The changes in mean scores from Rounds 1 to 2 are presented in Figures 1 
(patients/caregivers) and 2 (health professionals). Between the two rounds, the mean 
scores for each outcome were generally stable with the top 10 outcomes consistent 
across both rounds (Tables S3, S5). Patient/caregiver mean scores increased between 
rounds for the following four outcomes: life participation (mean score difference, 
0.27, p=0.006), ESKD (0.19, p=0.005), kidney function (0.14, p=0.02) and kidney 
cyst size/growth (0.15, p=0.049). For health professionals, mean scores increased for 
five outcomes from Round 1 to 2: death (0.33, p=0.002), cardiovascular disease (0.30, 
p=0.003), chronic pain (0.21, p=0.049), ESKD (0.20, p=0.002), and blood pressure 
(0.19, p=0.04). In Round 2, more health professionals rated blood pressure (Round 1 
vs. 2: 82% vs. 89%, p=0.02), cardiovascular disease (81 vs. 88%, p=0.007), and 
fatigue (50% vs. 55%, p=0.04) as critically important compared to Round 1. Kidney 
function (95% vs. 98%, p=0.007) and life participation (73% vs. 79%, p=0.002) were 
the only outcomes with higher proportion of patients/caregivers who rated it to be 
critically important compared to Round 1 (Figure 4).  
 
Differences between stakeholder groups  
Differences in mean scores between patients/caregivers and health professionals for 
Rounds 1 and 2 are shown in Figure 3. Of the 17 outcomes in Round 2, 
patients/caregivers rated 14 outcomes higher than health professionals on the Likert 
scale, with the greatest difference in scores for liver cyst (absolute mean difference, 
0.81, p<0.001), fatigue (0.74, p<0.001) and kidney cyst size/growth (0.68, p<0.001). 
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Death was the only outcome which was rated higher on the Likert scale by the health 
professionals (0.37, p=0.001). The differences in mean scores were comparable 
between the two participant groups for hospitalization (0.05, p=0.65) and ESKD 
(0.07, p=0.26). Similar differences were observed when results were analyzed by 
comparing proportions of “critically important” outcomes between patients/caregivers 
and health professionals (Figure 4).  
 
Best-Worst Scale 
In the BWS survey, both stakeholder groups identified ESKD as the most important 
outcome, but there were notable differences in the subsequent order of outcomes 
(Figure 5, Figures S2-4). Patients and caregivers prioritized ESKD, kidney function, 
cerebral aneurysm, cardiovascular disease and blood pressure in descending order, 
whereas health professionals considered death to be the second most important 
outcome, followed by kidney function and cardiovascular disease. Patients and 
caregivers identified chronic pain, kidney cyst size/growth, and kidney cyst 
pain/bleeding/infection to be as important as death. Results from the BWS survey 
were comparable for all participants when outcomes were analyzed according to 
language, except that kidney cyst size/growth was given higher priority by 
participants who completed the survey in Korean language. Patients and caregivers 
also highly rated chronic pain, which was the most important outcome among 
participants who completed the survey in French language. 
 
Thematic analysis  
Seven themes reflecting the reasons, changes and differences in the rating of 
outcomes were identified: protecting life and health, directly encountering life-
threatening and debilitating consequences, specificity to ADPKD, optimizing and 
15 
 
extending quality of life, hidden suffering, destroying self-confidence, and lost 
opportunities. The themes reflected the perspectives of all stakeholder groups unless 
otherwise specified. Illustrative quotations supporting each theme are provided in 
Table 3.  
 
Protecting life and health: Outcomes, such as blood pressure, kidney function and 
kidney cyst size/growth, were rated highly as they were considered important 
“biomarkers” to “keep healthy” and “to prevent damage”, to delay progression to 
ESKD or development of cardiovascular disease. Cerebral aneurysm was noted to be 
uncommon and not relevant to all patients with ADPKD but was rated highly due to 
its “life threatening” consequences.  
 
Directly encountering life-threatening and debilitating consequences: Some patients 
witnessed life-threatening consequences, such as premature death or severe disability 
involving their family members caused by cardiovascular disease and 
aneurysm/stroke, and these were thus rated critically important – “heart problems is 
what killed my father, who had PKD. His transplanted kidney was still working but 
his heart failed”. Other outcomes, such as ability to do usual activities (i.e. life 
participation), were prioritized based on having direct experience with outcomes that 
caused fear and frustration, “near end-stage, lots of activities are impossible. Very 
frustrating”.  
 
Specificity to ADPKD: Outcomes, such as cardiovascular disease, were considered, 
“important but not specific to ADPKD” and similar views were held for blood 
pressure which was, “not any more important in PKD than in any other kidney 




Optimizing and extending quality of life: Living with ADPKD was “long lasting” and 
patients were “more concerned with quality of life than survival” with lower scores 
for death among patients/caregivers compared to results from health professionals. 
Outcomes directly related to day-to-day symptom burden, such as kidney cyst 
size/growth, kidney cyst-related pain/bleeding/infection and chronic pain, were rated 
highly because they caused a “huge amount of morbidity”, which “has a big impact 
on day to day life”.  
 
Hidden suffering: Outcomes, including chronic pain, kidney cyst-related 
pain/bleeding/infection and mood, were rated highly by patients/caregivers because 
they were often “overlooked”, “minimized” and “misunderstood” by others. 
Moreover, these outcomes often led to “debilitating” symptom burden, which could 
be present “despite not being on dialysis (or anywhere near it).”  
 
Destroying self-confidence: For some patients, change in appearance or weight from 
ADPKD was critically important. It led to shattering “self-confidence - as the 
cysts/kidneys grew, it brought up issues other than just physical health. It’s harder to 
find well-fitting clothes and …. Can contribute to an existing feeling of sadness, 
anger, and despair” as well as “embarrassment and fear of social stigma.” Often 
patients felt they had “no control” over these outcomes.  
 
Lost opportunities: Financial impact was rated highly by some participants, who lost 
employment opportunities due to illnesses caused by ADPKD. Even if it was not 
directly experienced, participants recognized this to be an important concern – “many 
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PKD patients lose their jobs or face employment disciplinary procedures because of 
illness and hospitalizations”.  
 
DISCUSSION  
Kidney function, ESKD, death, blood pressure and kidney cyst size/growth were the 
highest prioritized outcomes in ADPKD among patients/caregivers and health 
professionals. Kidney cyst size/growth was in the top five outcomes for 
patients/caregivers only, whilst death was in the top five for health professionals only. 
Kidney cyst-related pain/bleeding/infection was the highest rated patient-reported 
outcome by both stakeholder groups, whereas other patient-reported outcomes, such 
as anxiety, muscle pain, itch/skin and sexual function, were deemed less important. 
Kidney pain due to cyst size/growth and infection/bleeding were highly prioritized 
due to their relentless symptom burden limiting life participation and as an indicator 
of disease progression towards ESKD. Similarly, other outcomes affecting quality of 
life, including liver cysts, financial impact and fatigue, were rated higher by 
patients/caregivers because these outcomes disrupted daily living and restricted their 
ability to fulfil their social roles and goals. In contrast, health professionals placed 
greater emphasis on death.  
 
Both patients/caregivers and health professionals consistently prioritized kidney 
function and ESKD as the most important outcomes in ADPKD. ESKD requiring 
kidney replacement therapy was a feared consequence to be avoided as it threatened 
quality of life, and kidney function was used to monitor progression to ESKD via its 
trajectory. The paramount importance attributed to kidney function and ESKD is in 
line with prior work on identifying outcomes important to patients with ADPKD and 
their caregivers14. Other outcomes with life-threatening or life changing 
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consequences, such as cerebral aneurysm and cardiovascular disease, and those 
believed to promote their occurrence, such as blood pressure, were also highly 
prioritized by both groups. Blood pressure may also have been perceived as critically 
important by patients and clinicians because hypertension is reported to affect up to 
70% of patients and often diagnosed around 30 years of age, usually prior to any 
apparent kidney dysfunction33-35. In contrast, surrogate outcomes perceived not to 
impose a similar risk of harm, such as anemia, proteinuria or lipids, were considered 
less important, even though these are frequently reported in ADPKD trials19.   
 
In general, health professionals gave lower priority to most outcomes compared to 
patients/caregivers except for three clinical outcomes, ESKD, death and 
hospitalization. Having direct experience of ADPKD, patients placed greater 
emphasis on life participation, indicating that they were limited by day-to-day 
symptom burden (e.g. cyst-related pain, fatigue) and its impact on practical aspects of 
life (e.g. financial impact). They rated these similarly to death in terms of relative 
importance. This finding also reinforces the profound impacts of ADPKD on lifestyle 
and wellbeing, which have been identified in previous studies14,15,36. Often these 
impacts have been perceived by patients to be underestimated by their physicians, and 
their symptom burden can result in dissatisfaction with care and treatment36. The high 
priority given to lifestyle-related outcomes has also been repeatedly shown in studies 
conducted in hemodialysis, peritoneal dialysis and kidney transplant 
populations27,28,37,38.  
 
Outcome domains related to cysts were prioritized highly by both stakeholder groups 
for different reasons. Health professionals, particularly from the Republic of Korea, 
rated kidney cyst size/growth highly due to its importance as a biomarker of disease 
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progression39. In contrast, patients/caregivers who completed the survey in French 
placed highest importance on chronic pain, due to its detrimental impact on quality of 
life. Patients from the Republic of Korea were also concerned about changes in 
physical appearance from enlarged cysts, which led to embarrassment and social 
stigma limiting their employment opportunities. Cyst-related outcomes were 
perceived to be underrecognized and inadequately managed, which in part explained 
the higher prioritization of these outcomes. Other studies have also shown that cyst-
related symptom burden is associated with worse quality of life and is a barrier to 
achieving long-term life goals17,18. An increase in economic burden from healthcare 
utilization due to cyst complications in ADPKD prior to clinically evident kidney 
dysfunction is now widely acknowledged15,40,41, and tools are being developed to 
better capture the cyst-related symptom burden of ADPKD (e.g. ADPKD-Impact 
Scale, GPRI-PKD)15,42.  
 
We have shown that kidney cyst-related pain/bleeding/infection was the most 
important patient-reported outcome. This is in contrast to other patient CKD 
populations (those receiving  hemodialysis43 and transplant44) where fatigue and life 
participation were identified as core patient-reported outcomes, respectively. This 
highlights the need for a core outcome set that is specific to ADPKD.  
 
This Delphi survey involved a large and diverse range of participants from 56 
countries with a high retention rate of 70% from Round 1 to 2. The survey was 
available in multiple languages to enable wider engagement. The qualitative data 
elucidated reasons that explain the prioritization of outcomes. However, there are 
some potential limitations. The survey did not measure details including ethnicity or 
stage of CKD to allow subgroup analysis. The number of surveys completed in 
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French (n=47) was relatively low compared to Korean (n=96) and English (n=461). 
Furthermore, the online mode of administration used to ensure wider participation 
precluded involvement from those without access to internet or limited computer 
literacy. However, the top prioritized outcomes in this study were similar to those 
identified in prior studies of patients with ADPKD elicited through other methods, 
such as focus groups and workshops14,17,18.   
 
In conclusion, the most important outcomes to patients/caregivers and health 
professionals were ESKD, kidney function, cerebral aneurysm and blood pressure. 
Kidney cyst pain and life participation were the most highly prioritized patient-
reported outcomes by patients/caregivers. Prior to finalizing the core set of outcome 
domains, public consultation will be sought through a Consensus Workshop involving 
patients, caregivers and health professionals, and any members of the public will be 
able to access the proposed core outcomes over a two-week time-frame and provide 
feedback through the SONG website.  All input will be reviewed and considered by 
the SONG-PKD Steering Group to establish a core outcome set.  Once a core 
outcome set has been identified, outcomes measures will be developed through a 
systematic process (systematic review and workshop) prior to its implementation in 
trials.  Establishing and implementing a core outcome set will help to improve the 
relevance and consistency of evidence to better inform shared decision-making for 







We thank all the patients, caregivers and health professionals who gave their time to 
participate in this study.  
 
Authors’ Contributions 
Research idea and study design: YC, GR, TG, CL, BS, JC, JC; data acquisition: YC, 
BS, CL, HR, TG, AT, ACNF, RAM, HH, MC, AKV; data analysis/interpretation: CL, 
YC, BS, HR, TG, AT, KM, AJ; statistical analysis: YC, ATP, BS, MH, KM, AT; 
supervision or mentorship: GR, RP, TH, JC, AO, AC, CA, HC, JK, RG, VT, YP, DJ, 
AT. Each author contributed important intellectual content during manuscript drafting 
or revision, accepts personal accountability for the author’s own contributions, and 
agrees to ensure that questions pertaining to the accuracy or integrity of any portion of 
the work are appropriately investigated and resolved.  
 
Support and financial disclosure declaration: 
YC is supported by a National Health and Medical Research Council (NHMRC) Early 
Career Fellowship (APP1126256). AT is supported by a NHMRC Fellowship 
(APP11067716). KEM is supported by a NHMRC Postgraduate Scholarship 
(APP1151343). DWJ is supported by a NHMRC Practitioner Fellowship 
(APP1117534). The study was financially supported by a grant from Polycystic 
Kidney Disease Foundation of Australia.  The funders or affiliated institutions played 
no role in study design; collection, analysis, and interpretation of data; writing the 






Table 1. Characteristics of patients/caregivers.  
Characteristic Round 1, n (%) 
603 participants 
Round 2, n (%) 
406 participants 









































































Did not complete high school  
















Current type of treatment (patients only) 
No kidney replacement therapy  
Peritoneal dialysis 
Hemodialysis 
















































Republic of Korea 
United States 





















aSome have multiple roles; bN ≠ 603 for rounds 1 due to missing data; *Other includes 22 countries (in descending order of 
number of participants): Norway, France, Singapore, Span, Netherlands, New Zealand, South Africa, China, Germany, Pakistan, 
Poland, Switzerland, Belarus, Denmark, Hong Kong, India, Ireland, Japan, Malaysia, Nepal, Nigeria, Turkey; cN = 361, 248 for 
round 1 and 2, respectively, due to missing data.  
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Table 2. Characteristics of health professionals.  
Characteristic Round 1, n (%) 
411 participants 
Round 2, n (%) 







































140 (46)  































































Republic of Korea 
United States 
Canada 
United Kingdom  
Singapore 






















aSome have multiple roles; bN ≠ 411 for round 1, due to missing data *Other includes 42 countries (in descending order): Italy, 
New Zealand, Japan, Spain, China, India, Portugal, Belgium, Argentina, Netherlands, Egypt, Germany, Greece, Lithuania, 
Malaysia, Pakistan, Poland, Thailand, Brazil, Finland, Nigeria, Philippines, Vietnam, Albania, Algeria, Austria, Belarus, Bosnia 
and Herzegovina, Bulgaria, Croatia, Denmark, Ecuador, El Salvador, Libya, Montenegro, Romania, Russia Federation, Slovakia, 






Table 3. Selected illustrative quotations  
Theme Illustrative Quotations  
Protecting life 
and health  
I like to know how my kidney is going so I am able to keep healthy (kidney function; Patient) 
Not common, but very life threatening (aneurysm/stroke; HP) 
BP to be controlled to prevent damage (BP; Patient) 
Cyst growth is associated with decline in kidney function and is an important surrogate outcome measure 
(cyst size/growth; HP) 
Reducing blood pressure can be beneficial for extending the loss of function of the kidney (BP; Patient)  
Kidney size is the most feared aspect of the disease for me. Very debilitating and absolutely ruins the way 
you look as well (cyst size/growth; Patient) 








Heart problems is actually what killed my father, who had PKD; his transplanted kidney was still working but 
his heart failed (CVD; PCG) 
My father died at 52 and had heart attack which caused transplant to fail and required bilateral amputee 
(CVD; PCG)  
My dad died of a heart attack, probably from uncontrolled BP (BP; PCG)  
When I was diagnosed (more than 40 years ago), I read in a medical dictionary that average age of death 
with PKD was 57. My dad died at 57. My sister died at 60. Death is critical outcome for me (death; PCG).  
I am in a wheelchair due to a brain bleed after going into cardiac arrest after having an aneurysm coiled 
(ability to do usual activities; Patient)  
Near end stage, lots of activities are impossible. Very frustrating (life participation; Patient)  




CVD is important but not specific to ADPKD so although should be reported in all trials in CKD not a specific 
outcome for ADPKD (CVD; HP) 
Optimising 
and extending 
quality of life 
PKD is usually long lasting. More concerned with quality of life than survival (death; Patient) 
Increased size can lead to decreased function and pain (cyst size/growth; Patient) 
Ability to function with enlarged kidneys (cyst size/growth; Patient) 
I suffer from constant chronic pain and it impacts on my quality of life so much (chronic pain; Patient) 
It has a big impact on day to day life (chronic pain; Patient) 
Hidden 
suffering  
Hidden symptom, feeling of being heavily pregnant, even though I’m slim (chronic pain; Patient)  
Despite not being on dialysis (or anywhere near it just yet), I still get kidney pain which fluctuates (chronic 
pain; Patient) 
I have been disability status based on my pain (chronic pain; Patient) 
Full abdomen feeling makes me think I’m full all the time (weight change; Patient)  
Mental and emotional health are so very important in getting through life with PKD (depression; Patient) 
I’ve had a couple of very serious cyst infections which caused agonising pain (cyst related pain/bleeding; 
Patient) 
In my experience this complication was overlooked and became quite painful and made me very sick (cyst 
infection; Patient)  
These are debilitating, painful and sometimes make people (patients and carers) feel hopeless (cyst 
infection; Patient). 
I think pain in PKD patients is hugely misunderstood by doctors and often overlooked (chronic pain; Patient)  
When mentioning pain physician tends to minimize this complaint (chronic pain; Patient)  
A lot of people do not understand how PKD can affect someone long term (impact on family/friends; Patient)  
Dealing with a disease for which there is no cure can really get to a person especially if you’re not getting 
support from family and friends. It’s hard to explain how you feel to someone who doesn’t have this disease 




For a patient, the importance of appearance is much underestimated. It’s all about self confidence, as the 
cysts/kidneys grow it brings up issues other than just physical health. It’s harder to find well fitting clothes 
and lack of confidence can contribute to an existing feeling of sadness, anger, despair (weight change; 
Patient) 
Huge belly is incredibly depressing and debilitating (appearance; Patient) 
I feel like I have no control over how people see me (appearance; Patient) 
Lost 
opportunities  
Lost my job, was too unwell to return (financial impact; Patient) 
Many PKDers lose their jobs or face employment disciplinary procedures because of illness and hospitals. 
People don’t get promoted I’m sure, or have to cut short their careers because of physical limitations 
(financial impact; Patient) 







Figure 1. Mean scores of patients/caregivers in rounds 1 and 2.  ESKD, end stage 
kidney disease 
 
Figure 2. Mean scores of health professionals in rounds 1 and 2. ESKD, end stage 
kidney disease 
 
Figure 3. Difference in mean scores between patients/caregivers and health 
professionals for rounds 1 and 2. Error bars refer to 95% confidence interval.  
 
Figure 4. Proportion of outcomes rated critically important (scores 7-9 using a 9-
point Likert scale), important (scores 4-6) and limited importance (scores 1-3) for 
patients/caregivers and health professionals in rounds 1 and 2. ESKD, end stage 
kidney disease.   
 
Figure 5. Mean relative importance scores of patients/caregivers and health 
professionals based on the Best-Worst Scale. Ordered by the mean importance scores 
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